

Sevil Yasar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4828060/publications.pdf>

Version: 2024-02-01

84
papers

4,077
citations

109264

35
h-index

118793

62
g-index

86
all docs

86
docs citations

86
times ranked

5109
citing authors

#	ARTICLE	IF	CITATIONS
1	Statin use in dementiaâ€”Review and comparison of guideline recommendations. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	2
2	CSF Biomarkers Predict Gait Outcomes in Idiopathic Normal Pressure Hydrocephalus. Neurology: Clinical Practice, 2022, 12, 91-101.	0.8	4
3	Association of Hearing Loss With Neuropsychiatric Symptoms in Older Adults With Cognitive Impairment. American Journal of Geriatric Psychiatry, 2021, 29, 544-553.	0.6	13
4	MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimer's and Dementia, 2021, 17, 704-715.	0.4	42
5	Assessing the predictive value of common gait measure for predicting falls in patients presenting with suspected normal pressure hydrocephalus. BMC Neurology, 2021, 21, 60.	0.8	6
6	Does the impact of intensive lifestyle intervention on cognitive function vary depending baseline level of frailty? An ancillary study to the Action for Health in Diabetes (Look AHEAD) Trial. Journal of Diabetes and Its Complications, 2021, 35, 107909.	1.2	0
7	Bloodâ€”Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease. Annals of Neurology, 2021, 90, 227-238.	2.8	57
8	Legacy of a 10-Year Multidomain Lifestyle Intervention on the Cognitive Trajectories of Individuals with Overweight/Obesity and Type 2 Diabetes Mellitus. Dementia and Geriatric Cognitive Disorders, 2021, 50, 237-249.	0.7	5
9	Evaluation of the effect comorbid Parkinson syndrome on normal pressure hydrocephalus assessment. Clinical Neurology and Neurosurgery, 2021, 207, 106810.	0.6	5
10	Developing Treatments for Alzheimerâ€™s and Related Disorders with Precision Medicine: A Vision. Advances in Experimental Medicine and Biology, 2021, 1339, 395-402.	0.8	2
11	Sex-Related Differences in Brain Volumes and Cerebral Blood Flow Among Overweight and Obese Adults With Type 2 Diabetes: Exploratory Analyses From the Action for Health in Diabetes Brain Magnetic Resonance Imaging Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 771-778.	1.7	14
12	Normal variations in brain oxygen extraction fraction are partly attributed to differences in end-tidal CO ₂ . Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1492-1500.	2.4	13
13	Association of cerebrovascular reactivity and Alzheimer pathologic markers with cognitive performance. Neurology, 2020, 95, e962-e972.	1.5	39
14	Lateâ€”onset epilepsy and 25â€”year cognitive change: The Atherosclerosis Risk in Communities (ARIC) study. Epilepsia, 2020, 61, 1764-1773.	2.6	16
15	Dementia in late-onset epilepsy. Neurology, 2020, 95, e3248-e3256.	1.5	45
16	Brain Oxygen Extraction Is Differentially Altered by Alzheimer's and Vascular Diseases. Journal of Magnetic Resonance Imaging, 2020, 52, 1829-1837.	1.9	33
17	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.5	78
18	Angiotensin II Blood Levels Are Associated with Smaller Hippocampal and Cortical Volumes in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2020, 75, 521-529.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Cerebrovascular reactivity mapping using intermittent breath modulation. <i>NeuroImage</i> , 2020, 215, 116787.	2.1	21
20	Standardized regression-based clinical change score cutoffs for normal pressure hydrocephalus. <i>BMC Neurology</i> , 2020, 20, 140.	0.8	3
21	Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 153-161.	1.2	15
22	Psychosocial Intervention in Couples Coping with Dementia Led by a Psychotherapist and a Social Worker: The DYADEM Trial. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 745-755.	1.2	14
23	Identification of Hearing Loss in Individuals With Cognitive Impairment Using Portable Tablet Audiometer. <i>Perspectives of the ASHA Special Interest Groups</i> , 2019, 4, 947-953.	0.4	6
24	Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 655-664.	1.2	11
25	Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 123-130.	1.7	69
26	Statin use and risk of Alzheimer disease. <i>Neurology</i> , 2018, 90, 103-104.	1.5	4
27	Natriuretic Peptides in Post-mortem Brain Tissue and Cerebrospinal Fluid of Non-demented Humans and Alzheimer's Disease Patients. <i>Frontiers in Neuroscience</i> , 2018, 12, 864.	1.4	13
28	Sex-related differences in the prevalence of cognitive impairment among overweight and obese adults with type 2 diabetes. <i>Alzheimer's and Dementia</i> , 2018, 14, 1184-1192.	0.4	23
29	Relation between alcohol consumption in midlife and dementia in late life. <i>BMJ: British Medical Journal</i> , 2018, 362, k3164.	2.4	4
30	The Association of Vitamin D Deficiency and Incident Frailty in Older Women: The Role of Cardiometabolic Diseases. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 619-624.	1.3	30
31	Alzheimer's disease pathology and shunt surgery outcome in normal pressure hydrocephalus. <i>PLoS ONE</i> , 2017, 12, e0182288.	1.1	28
32	Natriuretic peptides in the central nervous system: Novel targets for cognitive impairment. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 148-156.	2.9	28
33	Potentially Unsafe Activities and Living Conditions of Older Adults with Dementia. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1223-1232.	1.3	63
34	Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. <i>Current Hypertension Reports</i> , 2016, 18, 67.	1.5	27
35	Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies. <i>Current Hypertension Reports</i> , 2016, 18, 66.	1.5	17
36	P3-073: Association of angiotensin ii levels with cognition and MRI in older adults in the baltimore experience corps trial (BECT) brain health study. , 2015, 11, P645-P645.		0

#	ARTICLE	IF	CITATIONS
37	Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. <i>Neuropsychopharmacology</i> , 2015, 40, 2185-2197.	2.8	82
38	Lower Hemoglobin is Associated with Poorer Cognitive Performance and Smaller Brain Volume in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 972-973.	1.3	16
39	Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. <i>Addiction Biology</i> , 2013, 18, 30-39.	1.4	27
40	Antihypertensive drugs decrease risk of Alzheimer disease. <i>Neurology</i> , 2013, 81, 896-903.	1.5	184
41	Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction. , 2013, , 235-260.		2
42	Serum ceramides increase the risk of Alzheimer disease. <i>Neurology</i> , 2012, 79, 633-641.	1.5	176
43	Novel Use of a Lipid-Lowering Fibrate Medication to Prevent Nicotine Reward and Relapse: Preclinical Findings. <i>Neuropsychopharmacology</i> , 2012, 37, 1838-1847.	2.8	75
44	Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory study. <i>Alzheimer's and Dementia</i> , 2012, 8, 188-195.	0.4	20
45	Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 436-444.	0.7	108
46	An amyloid β 242-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1522-1532.	1.5	97
47	Combined effects of THC and caffeine on working memory in rats. <i>British Journal of Pharmacology</i> , 2012, 165, 2529-2538.	2.7	21
48	Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. <i>Biological Psychiatry</i> , 2011, 69, 633-641.	0.7	112
49	Effects of endocannabinoid system modulation on cognitive and emotional behavior. <i>Frontiers in Behavioral Neuroscience</i> , 2011, 5, 57.	1.0	167
50	Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. <i>Addiction Biology</i> , 2011, 16, 405-415.	1.4	50
51	Automatic recording of mediating behavior in delayed matching- and nonmatching-to-position procedures in rats. <i>Psychopharmacology</i> , 2011, 214, 495-504.	1.5	13
52	The Endogenous Cannabinoid 2-Arachidonoylglycerol Is Intravenously Self-Administered by Squirrel Monkeys. <i>Journal of Neuroscience</i> , 2011, 31, 7043-7048.	1.7	53
53	Evaluation of the Effect of Systolic Blood Pressure and Pulse Pressure on Cognitive Function: The Women's Health and Aging Study II. <i>PLoS ONE</i> , 2011, 6, e27976.	1.1	36
54	PRECLINICAL STUDY: FULL ARTICLE: Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR α nuclear receptors. <i>Addiction Biology</i> , 2010, 15, 277-288.	1.4	79

#	ARTICLE	IF	CITATIONS
55	Effect of Ginkgo biloba on Blood Pressure and Incidence of Hypertension in Elderly Men and Women. American Journal of Hypertension, 2010, 23, 528-533.	1.0	44
56	Peroxisome Proliferator-Activated Receptors-Alpha Modulate Dopamine Cell Activity Through Nicotinic Receptors. Biological Psychiatry, 2010, 68, 256-264.	0.7	92
57	Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR- γ nuclear receptors. Learning and Memory, 2009, 16, 332-337.	0.5	116
58	Anandamide-induced behavioral disruption through a vanilloid-dependent mechanism in rats. Psychopharmacology, 2009, 203, 529-538.	1.5	32
59	Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With Hypertension. Archives of Internal Medicine, 2009, 169, 1195.	4.3	199
60	Albuminuria and Dementia in the Elderly: A Community Study. American Journal of Kidney Diseases, 2008, 52, 216-226.	2.1	92
61	Fatty Acid Amide Hydrolase Inhibition Heightens Anandamide Signaling Without Producing Reinforcing Effects in Primates. Biological Psychiatry, 2008, 64, 930-937.	0.7	151
62	The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology, 2008, 54, 129-140.	2.0	132
63	Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors. Journal of Neuroscience, 2008, 28, 13985-13994.	1.7	164
64	Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist Rimonabant. Neuropsychopharmacology, 2008, 33, 2870-2877.	2.8	77
65	Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3- β -Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 482-490.	1.3	132
66	Would You Refer this Patient to Hospice? An Evaluation of Tools for Determining Life Expectancy in End-Stage Dementia. Journal of Palliative Medicine, 2007, 10, 1410-1419.	0.6	13
67	The Endogenous Cannabinoid Anandamide Produces γ -9-Tetrahydrocannabinol-Like Discriminative and Neurochemical Effects That Are Enhanced by Inhibition of Fatty Acid Amide Hydrolase but Not by Inhibition of Anandamide Transport. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 370-380.	1.3	103
68	Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacological Research, 2007, 56, 393-405.	3.1	86
69	Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nature Protocols, 2006, 1, 1194-1206.	5.5	116
70	A comparison of drug-seeking behavior maintained by d-amphetamine, l-deprenyl (selegiline), and d-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology, 2006, 183, 413-421.	1.5	12
71	Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)- β -Deprenyl]. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 387-394.	1.3	14
72	Nicotine may reinforce intravenous drug-taking behavior in drug users: reply to R. Dar and H. Frenk (2005). Psychopharmacology, 2005, 179, 518-519.	1.5	1

#	ARTICLE	IF	CITATIONS
73	Discriminative stimulus and reinforcing effects of p-fluoro-l-deprenyl in monkeys. Psychopharmacology, 2005, 182, 95-103.	1.5	6
74	Human Cocaine-Seeking Behavior and its Control by Drug-Associated Stimuli in the Laboratory. Neuropsychopharmacology, 2005, 30, 433-443.	2.8	41
75	Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology, 2004, 175, 134-42.	1.5	154
76	Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. European Journal of Pharmacology, 2003, 465, 257-265.	1.7	9
77	Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration. European Journal of Pharmacology, 2002, 439, 59-68.	1.7	38
78	Chronic caffeine exposure potentiates nicotine self-administration in rats. Psychopharmacology, 1999, 142, 327-333.	1.5	77
79	Behavioral effects of nicotine, amphetamine and cocaine under a fixed-interval schedule of food reinforcement in rats chronically exposed to caffeine. Psychopharmacology, 1998, 140, 257-271.	1.5	31
80	Methamphetamine Administration and Associated Neurotoxicity. , 1997, , 327-330.		0
81	Introduction: Examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline)*. Clinical Pharmacology and Therapeutics, 1994, 56, 721-724.	2.3	5
82	Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies*. Clinical Pharmacology and Therapeutics, 1994, 56, 768-773.	2.3	24
83	Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys*. Clinical Pharmacology and Therapeutics, 1994, 56, 774-780.	2.3	29
84	Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats. European Journal of Pharmacology, 1994, 259, 243-250.	1.7	11